This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
The opinions expressed by Dr. Ruth Darrow on the treatment of erythroblastosis fetalis (The Journal, April 28, p. 1146) are so greatly at variance with present concepts of this disease and its pathogenesis that we of the Blood Grouping Laboratory in Boston wish to draw your attention to certain proved facts concerning Rh sensitization and its recognition, together with the observations of many investigators on the best therapeutic procedures for the treatment of erythroblastotic infants.It is an accepted fact that the Rh positive erythrocyte has antigenic properties capable of stimulating Rh antibodies in an Rh negative person. The antigen may enter the body either directly by transfusion or via the placenta. Agglutinating antibodies (Rh agglutinins) resulting from such sensitization may be demonstrated by the proper laboratory methods as emphasized repeatedly by Levine and by Wiener. In some cases the severity of erythroblastosis in the infant appears
Diamond LK, Denton RL. TREATMENT OF ERYTHROBLASTOSIS FETALIS. JAMA. 1945;128(9):686. doi:10.1001/jama.1945.02860260060025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: